Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Green Cross HealthNZSE:GXH -5.02%64 Debt-to-EBITDA is 1.95 as of Mar. 2026, which is 7% below its 10-year median of 2.10. GuruFocus rates NZSE:GXH with a GF Score™ of 64/100 and a GF Value™ of NZ$1.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 482 Healthcare Providers & Services companies, Green Cross Health ranks better than 51.45% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Green Cross Health's Debt-to-EBITDA or its related term are showing as below:
NZSE:GXH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.26 Med: 2.1 Max: 3.18
Current: 2.15
During the past 13 years, the highest Debt-to-EBITDA Ratio of Green Cross Health was 3.18. The lowest was 1.26. And the median was 2.10.
NZSE:GXH's Debt-to-EBITDA is ranked better than 51.45% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.2
vs NZSE:GXH: 2.15
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Green Cross Health Debt-to-EBITDA Related Terms
Green Cross Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Green Cross Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Green Cross Health Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Green Cross Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Green Cross Health Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Green Cross Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Green Cross Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Green Cross Health (NZSE:GXH) has a Debt-to-EBITDA of 1.95 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Green Cross Health. This is near median its historical median of 2.10. Over the past decade, Green Cross Health's Debt-to-EBITDA has ranged from 1.26 to 3.18. According to the industry distribution chart, Green Cross Health ranks #234 out of 482 companies in the Healthcare Providers & Services industry, placing it in the top 48.5%.
Is Green Cross Health's Debt-to-EBITDA too high?
Green Cross Health's current Debt-to-EBITDA of 1.95 is near median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 3.18. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Green Cross Health's value of 1.95 is 11.4% below this industry median. Based on the distribution chart, Green Cross Health ranks #234 out of 482 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Green Cross Health has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Green Cross Health's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Green Cross Health ranks #234 out of 482 companies for Debt-to-EBITDA. This puts Green Cross Health in the upper half of its industry. The industry median Debt-to-EBITDA is 2.20. Green Cross Health's value of 1.95 is 11.4% below this benchmark. Historically, Green Cross Health's own Debt-to-EBITDA has ranged from 1.26 to 3.18 over the past decade. While the company's 10-year median is 2.10 vs. the industry median of 2.20, Green Cross Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Green Cross Health's current Debt-to-EBITDA of 1.95 is 11.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Green Cross Health. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Green Cross Health's current Debt-to-EBITDA is 1.95, which is near median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Green Cross Health stock overvalued right now?
Based on GuruFocus' analysis, Green Cross Health (NZSE:GXH) is currently considered Significantly Overvalued. The stock's GF Value™ is NZ$1.08, compared to a current price of NZ$1.99 — trading 83.8% above its estimated fair value. The current Debt-to-EBITDA is 1.95, which is near median its 10-year median of 2.10 and 11.4% below the Healthcare Providers & Services industry median of 2.20. Green Cross Health's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Green Cross Health (NZSE:GXH), the current Debt-to-EBITDA is 1.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Green Cross Health (NZSE:GXH) Overvalued in 2026?
Based on GuruFocus' analysis, Green Cross Health stock appears to be overvalued.
The current stock price of NZ$1.99 is trading 83.8% above its estimated GF Value™ of NZ$1.08.
GuruFocus considers Green Cross Health to be Significantly Overvalued.
Key valuation signals for NZSE:GXH:
Debt-to-EBITDA: 1.95 (near median its 10-year median of 2.10)
GF Value™: NZ$1.08 vs. price of NZ$1.99 (83.8% above fair value)
Industry Position: 11.4% below the Healthcare Providers & Services median (#234 of 482)
No single metric tells the full story. See the NZSE:GXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Green Cross Health Ltd is engaged in providing healthcare services in New Zealand. The reportable segments of the group are Pharmacy services and medical services. The majority of the revenue is generated from the Pharmacy services segment. The pharmacy services segment provides retail and dispensary services, and the medical services segment provides GP, nursing, and urgent care services. The majority of its revenue is generated from the pharmacy segment.
64GF Score
Get the complete analysis for NZSE:GXH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:GXH has been successfully added to your 
